Scroll Top
19th Ave New York, NY 95822, USA
Woman in white clothes holding virtual intestine in hand. Handrawn human organ, detox and healthcare, healthcare hospital service concept stock photo

ONCOSCREEN partner, the University Medical Centre Mainz (UMC-Mainz) is in attendance and sharing work at the the annual conference of the European Society for Medical Oncology (ESMO), which runs from the 13th to the 17th September, 2024. The comprehensive scientific programme of the ESMO supports the exchange and debate of cancer science in Europe – with participation from young and early career oncologists to distinguished and renowned experts from countries all over the world. The extensive five-day programme highlights new and potentially practice-changing data and puts emphasis on multidisciplinary discussions to expand and improve treatment options for patients.

First among the key learning objectives of the ESMO is the review and update on prevention, screening and early diagnosis of cancer. This year the educational session on ‘screening’ presented new developments in the exciting new field of multi-cancer screening, with the session entitled “The dark ages of single cancer screening is over” (see programme 12.09.24).

Speakers from France, UK and Israel talked about new and ongoing studies on multi- cancer early detection kits, about experiences of integrated cancer prevention centres, and the future potential of multi-cancer screening. Published authors include in this exciting new field include: Charles Swanton, UK; Robert Benamouzig, France and Nadir Arber, Israel.

Markus Möhler, the principal investigator of the ONCOSCREEN trails and head of the gastrointestinal oncology outpatient clinic from UMC Mainz, participated at the ESMO as a speaker and in two poster presentations about the results of the RATIONALE -305 Study (patients with G/GEJ adenocarcinoma) and a colorectal liver cancer study, as shown below:

  1. Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
  2. Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases

You can find more information about this event here:

https://www.esmo.org/meeting-calendar/esmo-congress-2024/programme